- Home
- CANF vs ARBEW Comparison
CANF vs ARBEW Comparison
Compare CANF & ARBEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ARBEW
- Stock Information
- Founded
- CANF 1994
- ARBEW 2015
- Country
- CANF Israel
- ARBEW Israel
- Employees
- CANF N/A
- ARBEW 144
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ARBEW EDP Services
- Sector
- CANF Health Care
- ARBEW Technology
- Exchange
- CANF Nasdaq
- ARBEW Nasdaq
- Market Cap
- CANF 13.5M
- ARBEW N/A
- IPO Year
- CANF N/A
- ARBEW N/A
- Fundamental
- Price
- CANF $1.03
- ARBEW $0.22
- Analyst Decision
- CANF Strong Buy
- ARBEW
- Analyst Count
- CANF 2
- ARBEW 0
- Target Price
- CANF $14.00
- ARBEW N/A
- AVG Volume (30 Days)
- CANF 146.4K
- ARBEW 32.4K
- Earning Date
- CANF 08-29-2025
- ARBEW 03-05-2025
- Dividend Yield
- CANF N/A
- ARBEW N/A
- EPS Growth
- CANF N/A
- ARBEW N/A
- EPS
- CANF N/A
- ARBEW N/A
- Revenue
- CANF $674,000.00
- ARBEW $768,000.00
- Revenue This Year
- CANF $461.72
- ARBEW N/A
- Revenue Next Year
- CANF N/A
- ARBEW N/A
- P/E Ratio
- CANF N/A
- ARBEW N/A
- Revenue Growth
- CANF N/A
- ARBEW N/A
- 52 Week Low
- CANF $0.98
- ARBEW $0.13
- 52 Week High
- CANF $4.69
- ARBEW $1.25
- Technical
- Relative Strength Index (RSI)
- CANF 43.30
- ARBEW N/A
- Support Level
- CANF $1.00
- ARBEW N/A
- Resistance Level
- CANF $1.09
- ARBEW N/A
- Average True Range (ATR)
- CANF 0.03
- ARBEW 0.00
- MACD
- CANF 0.00
- ARBEW 0.00
- Stochastic Oscillator
- CANF 45.00
- ARBEW 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ARBEW Arbe Robotics Ltd. Warrant
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.